Peaks of Interest
Millipore Corporation (Billerica, Massachusetts) announced that it recently has acquired over 90% of NovAseptic AB (Gothenburg, Sweden) shares. Millipore is in the process of acquiring the remaining shares from the minority shareholders.
Millipore acquires NovAseptic AB
Millipore Corporation (Billerica, Massachusetts) announced that it recently has acquired over 90% of NovAseptic AB (Gothenburg, Sweden) shares. Millipore is in the process of acquiring the remaining shares from the minority shareholders.
Martin Madaus, Millipore's chairman, CEO, and president, noted, "NovAseptic brings innovative and differentiated products that our biotech and pharmaceutical customers value highly for manufacturing biologics and for monitoring biomanufacturing processes."
NovAseptic provides a range of solutions for aseptic-processing applications in biotech and pharmaceutical manufacturing operations.
Market Profile: Mass Spectrometry
Applied Biosystems supports research into DNA signatures
The Translational Genomics Research Institute (Tgen, Pheonix, Arizona) and Northern Arizona University (NAU, Flagstaff, Arizona) announced recently the award of a multimillion dollar grant from the U.S. Department of Health and Human Services to improve the understanding of two leading causes of death for most age groups worldwide, sepsis and community-acquired pneumonia (CAP).
Applied Biosystems (Foster City, California) is supporting the project to discover pathogen-specific DNA signatures. These signatures will be used to design and validate Applied Biosystems TaqMan real-time PCR assays for the accurate identification of these life-threatening infections.
EMD opens chromatography center
EMD Chemicals, Inc. (Gibbstown, New Jersey) recently unveiled its new Chromatography Technical Center in Gibbstown, New Jersey. The center will be equipped with a wide range of chromatography columns and staffed by expert personnel.
The new center is expected to be operational by the end of 2005. Standard training sessions will be offered regularly, and custom-designed programs will be available to respond to individual customer scheduling and content requirements. In addition, EMD will continue to provide training at customer locations.
GTC Biotherapeutics receives notice of allowance on purification patent
GTC Biotherapeutics, Inc. (Framingham, Massachusetts) announced recently that the U.S. Patent and Trademark Office has issued a notice of allowance for the claims in its patent application 10/635,117 covering tangential flow filtration technology. These claims provide the company with a unique position in the use of this technology to recover recombinant therapeutic proteins that are expressed in the milk of transgenic animals.
The patent that issues from this application will expire in 2023.
Inverness Capital Partners invests in NCSRT to expand operations
Inverness Capital Partners (Philadelphia, Pennsylvania), a $125 million private equity fund, has invested in NCSRT, Inc. (Apex, North Carolina), a designer, developer, and manufacturer of filtration solutions.
Henry Kopf III, NCSRT president and CEO, says that the investment will allow NCSRT to expand operations and continue to provide customers with industry-leading technical support.
New Study Uses MSPE with GC–MS to Analyze PFCAs in Water
January 20th 2025Scientists from the China University of Sciences combined magnetic solid-phase extraction (MSPE) with gas chromatography–mass spectrometry (GC–MS) to analyze perfluoro carboxylic acids (PFCAs) in different water environments.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ion used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.
